EC
INZY

EntryPoint Capital’s Inozyme Pharma INZY Stock Holding History

EntryPoint Capital’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,460
Closed -$11.2K – 1246
2024
Q1 		$11.2K Buy
+1,460
New +$8.01K 0.01% 1217

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EntryPoint Capital's INZY Position: Q2 2024 in Review

EntryPoint Capital sold out of Inozyme Pharma (INZY) in Q2 2024, closing a stake of 1,460 shares — an estimated $11.2K sold.

EntryPoint Capital first reported a position in INZY in Q1 2024 and held it in 1 quarter. The position peaked at $11.2K in Q1 2024. 90 funds tracked by Wall St. Rank hold INZY as of Q2 2024.

  • EntryPoint Capital reported no remaining Inozyme Pharma position as of Q2 2024 after selling out during the quarter.
  • EntryPoint Capital sold 1,460 Inozyme Pharma shares in Q2 2024, an estimated $11.2K.
  • EntryPoint Capital first reported a position in Inozyme Pharma in Q1 2024 and held it in 1 quarter.
  • EntryPoint Capital's Inozyme Pharma position peaked at $11.2K in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.